* denotes a publication that resulted from CTD2 intra-Network collaborations
CTD2 researchers at UCSF showed that SHP2, a non-receptor protein tyrosine phosphatase, could be a potential molecular target in cancers driven by oncogenic mutants of RAS/MAPK pathway.
Review on the role of CDK12 as a clinical biomarker and as a potential therapeutic target for cancer therapy.
A review article on using the patient-derived cancer models for the identification of targets to overcome roadblocks of precision oncology.
Genome-scale open reading frame screen identifies RNA binding proteins, QK1 and RBFOX1, regulate the alternate splicing of actin binding protein, FLNB. The skipping of FLNB exon 30 is associated with the transition to mesenchymal- and stem-like cell states in breast cancer pathogenesis.
Scientists at DFCI demonstrated that binding of transcription factor, ERG, to chromatin remodeling complex, BAF, is essential to facilitate basal-to-luminal transition, a hallmark of prostate oncogenesis.
Researchers at UCSF developed an analytical framework for constructing a human genetic interaction map, a powerful tool to identify genetic interactions between genes and suggest new combination therapies for cancer.